Unlike conventional targeted antigens, LunX is often highly expressed only in the lung and nose, but hardly in other parts of the human body, and cell therapy using LunX-CAR-T may be a new means of treating NSCLC. Here, BPIFA1 is linked to non-small cell lung carcinoma.